Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan + Temozolomide in Recurrent Neuroblastoma
NCT00311584Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Apr 2006
- Primary completion
- Mar 2009
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and temozolomide in neuroblastoma (2 arms), sponsored by Children's Oncology Group. Primary endpoints: Overall Response Rate and Toxicities associated with irinotecan and temozolomide. Started Apr 2006; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabtemozolomide
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT00311584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00311584.